ArticleJTCVS open2026
Surgical nodal sampling established by Commission on Cancer Standard 5.8 is essential for accurate lung cancer staging.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Accurate mediastinal staging is critical for the effective treatment of non-small cell lung cancer because lymph node involvement significantly influences prognosis and therapeutic decisions. We sought to evaluate the diagnostic accuracy, limitations, and complementary roles of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), cervical mediastinoscopy, and surgical lymph node sampling in mediastinal staging of non-small cell lung cancer. Methods: A systematized literature review was performed using PubMed and national guideline repositories. Studies were included if they reported or provided sufficient data to calculate the negative predictive value (NPV) for EBUS-TBNA, mediastinoscopy, or surgical lymph node sampling. Data were synthesized qualitatively across different clinical scenarios. Results: The pooled (unweighted) NPV of EBUS-TBNA was 93.2% (range, 84.7%-98%). Mediastinoscopy demonstrated a pooled NPV of 93.8% (range, 78.8%-97%), with most false negatives attributable to inaccessible stations. Surgical lymph node sampling yielded a pooled NPV of 92.2% (range, 83.6%-96%) for resected nodal stations, although assessment is limited by variability across studies with inconsistent surgical approaches. These data support the need for systematic intraoperative nodal evaluation to confirm pathologic stage and inform treatment selection. Conclusions: Although EBUS-TBNA is the preferred initial staging modality due to its minimally invasive nature, its diagnostic limitations warrant a low threshold for additional nodal evaluation. Systematic intraoperative lymph node evaluation at the time of surgical resection is indispensable for definitive staging, providing clinically actionable data that influences treatment decisions. Optimal staging of non-small cell lung cancer requires a multidisciplinary, individualized approach that combines modalities based on pretest probability, imaging findings, and patient factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.